Volume 12 | July 2020
Kidney Cancer News
KidneyCAN is excited to present our plan for at-home advocacy this summer! In August, when our congressional representatives will be at home in their districts, we are making a plan for our community to engage in District Days. 

District Days will give the kidney cancer community an opportunity to share their stories and experiences with their representatives. This communication is vital to the process of securing funding for kidney cancer research. 

Please plan to join us! We want all our participants to feel safe and will continue to monitor the Covid landscape making necessary changes to in-person House meetings to reduce all risks.

You don’t need to be a trained advocate, and you won’t need any special tools or skills. You just need a passion for our cause. We’ll help with the rest!
KidneyCan participated in World Kidney Cancer Day , which took place on June 18th. The theme this year was "Let's talk about physical activity," the benefits of physical activity for kidney cancer patients. We had many wonderful Smart Patient stories that were contributed and shared on Facebook and Twitter throughout the day. We also hosted a Facebook Live event with Total Health Conferencing. The event can still be viewed HERE .

Dr Toni Choueiri speaks to ecancer at the  2020 ASCO GU  meeting in San Francisco about the latest developments in renal cancer.
More than 80 delegates attended live and dozens more live-streamed the presentations at the 12th annual Dana-Farber/Harvard Cancer Center Kidney Cancer Symposium in Boston, Massachusetts.The free event was included some of the best medical practitioners from around the country and was designed to be an opportunity for education and advocacy.
Fotivda (tivozanib) significantly improved survival, compared with Nexavar (sorafenib), in patients with highly relapsed or refractory metastatic renal cell carcinoma (RCC), according to results from the phase 3 TIVO-3 trial presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.
It is known that tumor RNA profiling via RNA sequencing has the potential to identify mechanisms of resistance to immune checkpoint blockade. Several studies of anti PD-L1 or anti-VEGF combination therapy have been done to evaluate the tumour molecular profiles of patients with advanced renal cell carcinoma. This was done to help inform future strategies to personalize therapies.
Yousef Zakharia, MD, discusses the next steps after the phase 1 trial of seleno-L-methionine in combination with axitinib as treatment of adult patients with previously treated or relapsed clear cell renal cell carcinoma.
KIdneyCAN is the voice of kidney cancer advocacy. We have been instrumental in obtaining $40 million for FY'20 research funding for Kidney Cancer through the DoD CDMRP Program. Our goal is $50 million for kidney cancer research in FY'21.

Please consider supporting KidneyCAN's Advocacy for research and direct research funding.
About The KidneyCAN Newsletter: We scan the web for the latest relevant research and share the best here. If we missed a great one, please contact us and share it with us.

We need your help to get the word out . Please sign up your friends for the newsletter, both patients and caregivers. Share this newsletter on Facebook, Twitter or Instagram .

And come talk with kidney cancer patients (including us) on SmartPatients.com

Disclaimer: The material in this newsletter is for informational purposes only and is not a substitute for professional medical advice. Consult with a qualified healthcare provider with any questions or concerns you may have.
KidneyCAN/ Kidney Cancer Coalition | Tel: 202-431-2727 | Bryan.Lewis@KidneyCAN.org